Candel Therapeutics, Inc. (CADL)
NASDAQ$8.75
Market Cap
$389.16M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
53 of 924
Rank in Industry
38 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
CADL Insider Trading Activity
CADL Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $7,500,000 | 1 | 3 |
Sells | $2,899,823 | 30 | 97 |
Related Transactions
| Manning Paul B | director | 1 | $7.5M | 0 | $0 | $7.5M |
| Schoch Charles | See Remarks | 0 | $0 | 4 | $267,781 | $-267,781 |
| Nichols William Garrett | Chief Medical Officer | 0 | $0 | 5 | $356,318 | $-356,318 |
| Barone Francesca | Chief Scientific Officer | 0 | $0 | 5 | $477,223 | $-477,223 |
| Aguilar-Cordova Estuardo | 10 percent owner | 0 | $0 | 6 | $486,476 | $-486,476 |
| Tyagarajan Seshu | Chief Technology Officer | 0 | $0 | 5 | $491,658 | $-491,658 |
| Tak Paul Peter | Chief Executive Officer | 0 | $0 | 5 | $820,367 | $-820,367 |
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of …
Insider Activity of Candel Therapeutics, Inc.
Over the last 12 months, insiders at Candel Therapeutics, Inc. have bought $7.5M and sold $2.9M worth of Candel Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Candel Therapeutics, Inc. have bought $7.46M and sold $2.9M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Manning Paul B (director) — $7.5M.
The last purchase of 1,250,000 shares for transaction amount of $7.5M was made by Manning Paul B (director) on 2024‑12‑16.
List of Insider Buy and Sell Transactions, Candel Therapeutics, Inc.
| 2025-01-15 | Sale | Tak Paul Peter | Chief Executive Officer | 21,704 0.0476% | $7.22 | $156,811 | +0.94% | |
| 2025-01-15 | Sale | Barone Francesca | Chief Scientific Officer | 13,534 0.0297% | $7.22 | $97,783 | +0.94% | |
| 2025-01-15 | Sale | Tyagarajan Seshu | Chief Technology Officer | 14,322 0.0314% | $7.22 | $103,476 | +0.94% | |
| 2025-01-15 | Sale | Nichols William Garrett | Chief Medical Officer | 10,428 0.0229% | $7.22 | $75,342 | +0.94% | |
| 2025-01-15 | Sale | Schoch Charles | See Remarks | 9,511 0.0209% | $7.22 | $68,717 | +0.94% | |
| 2025-01-08 | Sale | Tak Paul Peter | Chief Executive Officer | 21,172 0.0454% | $8.22 | $173,996 | -8.19% | |
| 2025-01-08 | Sale | Barone Francesca | Chief Scientific Officer | 13,673 0.0293% | $8.22 | $112,367 | -8.19% | |
| 2025-01-08 | Sale | Tyagarajan Seshu | Chief Technology Officer | 14,545 0.0312% | $8.22 | $119,534 | -8.19% | |
| 2025-01-08 | Sale | Nichols William Garrett | Chief Medical Officer | 10,799 0.0231% | $8.22 | $88,749 | -8.19% | |
| 2025-01-08 | Sale | Schoch Charles | See Remarks | 9,971 0.0214% | $8.22 | $81,944 | -8.19% | |
| 2024-12-16 | Manning Paul B | director | 1.25M 3.786% | $6.00 | $7.5M | +33.12% | ||
| 2024-11-29 | Sale | Tak Paul Peter | Chief Executive Officer | 48,847 0.1456% | $4.56 | $222,527 | +70.17% | |
| 2024-11-29 | Sale | Barone Francesca | Chief Scientific Officer | 22,081 0.0658% | $4.56 | $100,592 | +70.17% | |
| 2024-11-29 | Sale | Tyagarajan Seshu | Chief Technology Officer | 20,392 0.0608% | $4.56 | $92,898 | +70.17% | |
| 2024-11-29 | Sale | Nichols William Garrett | Chief Medical Officer | 13,935 0.0415% | $4.56 | $63,482 | +70.17% | |
| 2024-10-15 | Sale | Aguilar-Cordova Estuardo | 10 percent owner | 10,412 0.0279% | $6.03 | $62,784 | +17.82% | |
| 2024-10-14 | Sale | Aguilar-Cordova Estuardo | 10 percent owner | 15,000 0.0401% | $6.02 | $90,300 | +16.00% | |
| 2024-10-11 | Sale | Aguilar-Cordova Estuardo | 10 percent owner | 15,000 0.0403% | $6.05 | $90,750 | +15.03% | |
| 2024-10-03 | Sale | Aguilar-Cordova Estuardo | 10 percent owner | 1,800 0.0055% | $6.85 | $12,330 | +0.22% | |
| 2024-10-02 | Sale | Aguilar-Cordova Estuardo | 10 percent owner | 26,988 0.083% | $6.92 | $186,757 | -1.47% |
Total: 49
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Manning Paul B | director | 1303752 2.9314% | $11.41M | 3 | 0 | <0.0001% |
| Tak Paul Peter | Chief Executive Officer | 251912 0.5664% | $2.2M | 3 | 5 | <0.0001% |
| Barone Francesca | Chief Scientific Officer | 110673 0.2488% | $968,388.75 | 1 | 5 | <0.0001% |
| Tyagarajan Seshu | Chief Technology Officer | 96790 0.2176% | $846,912.50 | 2 | 5 | <0.0001% |
| Martell Christopher | director | 152000 0.3418% | $1.33M | 3 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$84,871,118 | 57 | 17.71% | $412.59M | |
$109,415,500 | 33 | 18.13% | $353.41M | |
$26,923,982 | 20 | -17.22% | $407.13M | |
$73,222,926 | 18 | 60.19% | $406.4M | |
Candel Therapeutics, Inc. (CADL) | $14,865,077 | 18 | -28.56% | $389.16M |
CADL Institutional Investors: Active Positions
| Increased Positions | 52 | +173.33% | 13M | +198.34% |
| Decreased Positions | 11 | -36.67% | 60,779 | -0.91% |
| New Positions | 21 | New | 8M | New |
| Sold Out Positions | 2 | Sold Out | 14,876 | Sold Out |
| Total Postitions | 71 | +136.67% | 20M | +197.43% |
CADL Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Fmr Llc | $35,214.00 | 9.34% | 3.92M | +4M | +59,592.67% | 2024-12-31 |
| Baker Bros. Advisors Lp | $26,763.00 | 7.1% | 2.98M | +3M | New | 2024-12-31 |
| Acorn Capital Advisors, Llc | $17,408.00 | 4.62% | 1.94M | +2M | New | 2024-12-31 |
| Northpond Ventures, Llc | $17,369.00 | 4.61% | 1.94M | 0 | 0% | 2024-09-30 |
| Braidwell Lp | $14,360.00 | 3.81% | 1.6M | +2M | New | 2024-12-31 |
| Vanguard Group Inc | $12,019.00 | 3.19% | 1.34M | +392,885 | +41.52% | 2024-12-31 |
| Blackrock, Inc. | $10,626.00 | 2.82% | 1.18M | +58,268 | +5.18% | 2024-12-31 |
| Portolan Capital Management, Llc | $6,765.00 | 1.8% | 753,745 | +753,745 | New | 2024-12-31 |
| Halter Ferguson Financial Inc. | $6,115.00 | 1.62% | 681,334 | +376,795 | +123.73% | 2024-12-31 |
| State Street Corp | $5,035.00 | 1.34% | 560,969 | +68,964 | +14.02% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.